Trial Profile
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children With Relapsed Solid Tumor, Lymphoma or Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Leukaemia; Lymphoma; Solid tumours
- Focus Adverse reactions
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 14 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.